Hoth Therapeutics, Inc., a company in the clinical stage of biopharmaceuticals that specializes in creating new treatments, is excited to share the news of receiving a US patent for their cutting-edge Alzheimer's treatment, HT-ALZ...
OKYO Pharma Limited, a company in the clinical stage of biopharmaceutical development, is creating new treatments for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP). This billion-dollar market lacks FDA-approved therapy for...
Circle Pharma, Inc., a company focused on finding and creating new macrocycle therapies, disclosed that the initial group of patients has been given doses in the phase 1 study of CID-078, their groundbreaking oral cyclin A/B RxL inhibitor...
.webp)
Bayer and MOMA Therapeutics, Inc., a biopharmaceutical company in the clinical stage that focuses on discovering and creating precise therapeutics, have declared a collaboration. This partnership involves an option and exclusive license agreement...
Aurigene Oncology Limited, a subsidiary of Dr Reddy’s Laboratories Limited, is dedicated to developing innovative treatments for cancer and has released phase 1 findings for DRL-1801 in the SWASTH study - India's initial trial for a new CAR-T cell...
Boehringer Ingelheim, a biopharmaceutical company involved in human and animal health, revealed that the FDA has given Breakthrough Therapy status to survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist for treating adults with non...
GE Healthcare, a top international company in medical technology, pharmaceutical diagnostics, and digital solutions, has finished the first stage of testing for a unique MRI contrast agent made from manganese. According to an abstract presented at...
In an exclusive interview with India Pharma Outlook, DileepMangsuli, Senior Vice President of Global Access to Care at Siemens Healthineers, shared his views on how AI can transform personalized healthcare. AI, he emphasizes a dual-layer approach....
TiumBio Co., Ltd, a company specializing in biopharmaceuticals in the clinical development stage, revealed that the initial participant has been administered in the phase 2 clinical study of TU2218. TU2218 is a new oral inhibitor that targets both...
Sapience Therapeutics, Inc., a biotechnology company in the clinical stage, has reported the enrollment of the initial patient in its phase 2 dose expansion study for ST316, the company's innovative antagonist of b-catenin. The study's phase 1...
, CDSCO.jpg)
